Home/Pipeline/M2 Macrophage Therapy

M2 Macrophage Therapy

Graft‑Versus‑Host Disease (GVHD)

Phase 1Active

Key Facts

Indication
Graft‑Versus‑Host Disease (GVHD)
Phase
Phase 1
Status
Active
Company

About Cytopeutics

MSC‑based cell therapy platform with halal‑certified products for Asia‑Pacific clinical markets.

View full company profile